Treatment with Brentuximab Vedotin Plus Bendamustine in Unselected Patients with CD30-positive Aggressive Lymphomas

Overview

Journal Eur J Haematol

Specialty Hematology

Date 2019 Dec 16

PMID 31838747

Citations 8

Authors

Sandro M Wagner

Thomas Melchardt

Alexander Egle

Teresa Magnes

Cathrin Skrabs

Philipp Staber

Ingrid Simonitsch-Klupp

Michael Panny

Barbara Lehner

Richard Greil

Felix Keil

Ulrich Jager

Christian Sillaber

Affiliations

Soon will be listed here.

Abstract

Objectives: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lymphoma (cHL). In this retrospective analysis, we aimed to assess this therapy's efficacy in unselected patients with cHL and CD30+ peripheral T-cell lymphoma (PTCL).

Patients And Methods: Data of 28 patients with cHL and five patients with PTCL treated with a combination of bendamustine and BV at three Austrian tertiary cancer centers were analyzed.

Results: In patients with cHL, the ORR was 100% (78.6% CR, 21.4% PR). After 17 months median follow-up, median survival times were not reached; 1-year PFS was 81.9%, and 1-year OS was 95.7%. Thirteen eligible patients (46.4%) successfully underwent planned ASCT after salvage therapy with bendamustine and BV and subsequent high-dose chemotherapy. Three of the five PTCL patients achieved CR, while two did not respond and died during or shortly after therapy.

Conclusion: A combination of bendamustine and BV is an effective salvage and induction therapy before ASCT in patients with relapsed/refractory cHL. Further research is warranted to evaluate the use in patients with PTCL.

Citing Articles

Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T-cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report.

De Wilde S, Graux C Clin Case Rep. 2024; 12(7):e9159.

PMID: 38979088 PMC: 11228349. DOI: 10.1002/ccr3.9159.

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.

Chang E, Tan Y, Chan J J Hematol Oncol. 2024; 17(1):38.

PMID: 38824603 PMC: 11144347. DOI: 10.1186/s13045-024-01560-7.

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.

Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P Blood Adv. 2022; 7(19):5733-5742.

PMID: 36477770 PMC: 10539874. DOI: 10.1182/bloodadvances.2022008524.

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.

Gentille C, Sarfraz H, Joshi J, Randhawa J, Shah S, Pingali S Cancer Rep (Hoboken). 2022; 5(7):e1581.

PMID: 35263030 PMC: 9327648. DOI: 10.1002/cnr2.1581.

Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease).

Kazemian A, Nematollahi P J Res Med Sci. 2021; 26:90.

PMID: 34899928 PMC: 8607176. DOI: 10.4103/jrms.JRMS_1024_20.

References

Chen R, Palmer J, Martin P, Tsai N, Kim Y, Chen B . Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015; 21(12):2136-2140. PMC: 4639410. DOI: 10.1016/j.bbmt.2015.07.018. View

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez A, Pinana J . Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019; 30(4):612-620. DOI: 10.1093/annonc/mdz009. View

Labrador J, Cabrero-Calvo M, Perez-Lopez E, Mateos M, Vazquez L, Caballero M . ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol. 2014; 93(10):1745-53. DOI: 10.1007/s00277-014-2114-0. View

Horwitz S, Advani R, Bartlett N, Jacobsen E, Sharman J, OConnor O . Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 123(20):3095-100. PMC: 4425442. DOI: 10.1182/blood-2013-12-542142. View

Connors J, Jurczak W, Straus D, Ansell S, Kim W, Gallamini A . Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2017; 378(4):331-344. PMC: 5819601. DOI: 10.1056/NEJMoa1708984. View

Poenisch W, Plotze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T . Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol. 2015; 141(11):2013-22. DOI: 10.1007/s00432-015-1984-4. View

Wagner S, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P . Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. Eur J Haematol. 2019; 104(3):251-258. PMC: 7065019. DOI: 10.1111/ejh.13368. View

Josting A, Muller H, Borchmann P, Baars J, Metzner B, Dohner H . Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010; 28(34):5074-80. DOI: 10.1200/JCO.2010.30.5771. View

Budde L, Wu D, Martin D, Philip M, Shustov A, Smith S . Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2019; 183(4):601-607. PMC: 6314205. DOI: 10.1111/bjh.15585. View

10.

Ribrag V, Nasr F, Bouhris J, Bosq J, Brault P, Girinsky T . VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant. 1998; 21(10):969-74. DOI: 10.1038/sj.bmt.1701202. View

11.

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

12.

Moskowitz A, Yahalom J, Kewalramani T, Maragulia J, Vanak J, Zelenetz A . Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23):4934-7. PMC: 3799204. DOI: 10.1182/blood-2010-05-282756. View

13.

Moskowitz C, Nimer S, Zelenetz A, Trippett T, Hedrick E, Filippa D . A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97(3):616-23. DOI: 10.1182/blood.v97.3.616. View

14.

Greil R, Pleyer L, Jansko B, Feierabend C, Rettenbacher L, Stiefel O . Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations. Oncotarget. 2018; 9(29):20928-20940. PMC: 5945535. DOI: 10.18632/oncotarget.25037. View

15.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E . Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2012; 31(1):104-10. DOI: 10.1200/JCO.2012.43.7285. View

16.

Horwitz S, OConnor O, Pro B, Illidge T, Fanale M, Advani R . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2018; 393(10168):229-240. PMC: 6436818. DOI: 10.1016/S0140-6736(18)32984-2. View

17.

Dumont M, Ram-Wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M . Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas. Br J Dermatol. 2019; 181(6):1315-1317. DOI: 10.1111/bjd.18215. View

18.

OConnor O, Lue J, Sawas A, Amengual J, Deng C, Kalac M . Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2017; 19(2):257-266. PMC: 9098158. DOI: 10.1016/S1470-2045(17)30912-9. View

19.

LaCasce A, Bociek R, Sawas A, Caimi P, Agura E, Matous J . Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018; 132(1):40-48. PMC: 6073588. DOI: 10.1182/blood-2017-11-815183. View

20.

Friedberg J, Forero-Torres A, Bordoni R, Cline V, Patel Donnelly D, Flynn P . Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017; 130(26):2829-2837. DOI: 10.1182/blood-2017-06-787200. View